Back to results

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

Primary Purpose

Malaria, Plasmodium Falciparum Malaria

Status

Completed

Phase

Phase 1

Locations

Tanzania

Study Type

Interventional

Intervention

PfSPZ Vaccine

Normal Saline (Placebo)

PfSPZ Challenge

About this trial

This is an interventional prevention trial for Malaria focused on measuring Malaria, Plasmodium falciparum malaria, PfSPZ Vaccine, PfSPZ Challenge, Controlled human malaria infection (CHMI)

Eligibility Criteria

18 Years - 35 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

Healthy male aged between 18 - 35 years.
Good health status based on history and clinical examination.
Long term or permanent resident in or near Dar-es-Salaam.
Able and willing to complete the study visit schedule over the one year follow up period, including the hospitalizations required for protocol compliance.
Able and willing to complete the informed consent process conducted in English.
Demonstrate understanding of the study and procedures by answering 20 questions from the Protocol & Study Procedures Understanding Checklist correctly with a maximum of two attempts.
Agrees to inform study doctor of medical conditions and contraindications for participation in the study.
Agrees to provide contact information to the study team for a household member who will serve as an emergency contact during trial participation.
Willing to be attended by a study doctor and take medications, which may be prescribed by a study doctor, during study participation.
Reachable (24/7) by mobile phone during the whole study period.
Agrees not to participate in another study during the study period.
Agrees not to donate blood during the study period.
Willing to undergo HIV, hepatitis B and hepatitis C testing.
Willing to undergo controlled human malaria infection (CHMI).

Exclusion Criteria:

History of malaria in the past 5 years.
Positive for malaria by thick blood smear at screening.
Plans to travel outside the Dar-es-Salaam or Coast Region in first 12 months of the study.
Previous receipt of an investigational malaria vaccine.
Antibodies to parasites or selected parasite protein(s) above acceptable cut off established for the site
History of arrhythmias or prolonged QT-interval or other cardiac disease or clinically significant abnormalities in electrocardiogram (ECG) at screening.
History or indication of a history of drug or alcohol abuse interfering with normal social function.
Use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study enrollment (inhaled and topical corticosteroids are allowed).
Ongoing condition that could interfere with the interpretation of the study results or compromise the health of the volunteer.
History of diabetes mellitus or cancer.
Body Mass Index (BMI) below 18 or above 30 kg/m2.
Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes.
Positive HIV, Hepatitis B virus or Hepatitis C virus tests.
Participation in any other clinical study within 30 days prior to study enrollment.
Known hypersensitivity, allergy, or other contra-indications to Coartem® or Malarone® including treatment taken by the volunteer that interferes with Coartem® or Malarone®.
Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia.
Heterozygous or homozygous for sickle cell or homozygous for alpha thalassemia.
Glucose-6-phosphate dehydrogenase deficiency
Psychiatric condition that precludes compliance with the protocol; past or present psychoses; disorder requiring lithium; or within five years prior to enrollment, history of suicide plan or attempt.
Any medical, psychiatric, social condition, or occupational reason that, in the judgment of the investigator, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent, increases the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
History of 3 or more other immunizations within the six months before administration of the first dose of vaccine.
Clinically active tuberculosis

Sites / Locations

Bagamoyo Research and Training Center, Ifakara Health Institute, Kingani Estate, PO Box 74

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Group 1

Group 2(A)

Group 2(B)

Group 3(A)

Group 3(B)

Group 4

Group 5

Arm Description

Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10^4, 1.35x10^5, and 2.7x10^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.

Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).

Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).

Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).

Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).

The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.

The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.

Outcomes

Primary Outcome Measures

Safety and tolerability endpoints

Solicited local (IV site) and systemic AEs (AEs) observed in the 7 days after each vaccination and each CHMI. Unsolicited AEs observed after the first vaccination until day 28 after the last vaccination for volunteers who do not undergo CHMI#1 (e.g. Group 1, those who do not complete the CHMI portion in Groups 2 and 3, and volunteers in Group 4). Unsolicited AEs observed after the first vaccination until day 28 after the CHMI#1 for volunteers who undergo CHMI#1 3 weeks after the last vaccination (e.g. Groups 2 and 3). Unsolicited AEs observed from day CHMI#2 (which occurs 24 weeks after the last vaccination) until day 28 after CHMI#2 (e.g. Groups 2-5).

Protective Efficacy after CHMI with PfSPZ Challenge (NF54) - CHMI Endpoints

Number of volunteers that remain parasite negative in each group through day 28 of follow up after CHMI with PfSPZ Challenge (NF54) IV inoculation. Three weeks after their last immunization, volunteers in Groups 2 and 3 will under go their first CHMI with 3.2 x 10^3 PfSPZ Challenge (NF54) administered IV. Twenty-four weeks after the last immunization, volunteers from Groups 2 and 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). Volunteers in Groups 4 and 5 will only participate in the second CHMI assessment. After CHMI, volunteers will be followed for evidence of infection with blood smears for 28 days.

Secondary Outcome Measures

Immune Responses after PfSPZ Vaccine

Cellular and humoral immune responses will be assessed in the vaccinated volunteers and controls (including central and effector memory responses and breadth and specificity of malaria antibodies).

Protective effect of the high dose PfSPZ Vaccine regimen

Number of volunteers negative in Group 3 and Group 4 compared to Group 2 through day 28 of follow up after homologous PfSPZ Challenge (NF54) IV inoculation.

Full Information

NCT ID

NCT02132299

First Posted

April 29, 2014

Last Updated

April 25, 2016

Sponsor

Sanaria Inc.

Collaborators

Ifakara Health Institute, Swiss Tropical & Public Health Institute, Tanzania Commission for Science and Technology

1. Study Identification

Unique Protocol Identification Number

NCT02132299

Brief Title

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

Official Title

Phase 1, Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

Study Type

Interventional

2. Study Status

Record Verification Date

April 2016

Overall Recruitment Status

Completed

Study Start Date

April 2014 (undefined)

Primary Completion Date

July 2015 (Actual)

Study Completion Date

August 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sanaria Inc.

Collaborators

Ifakara Health Institute, Swiss Tropical & Public Health Institute, Tanzania Commission for Science and Technology

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This trial will evaluate whether relatively non-immune populations in endemic countries can effectively generate significant cellular and humoral immune responses that confer protection against P. falciparum infection after inoculation of aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) Plasmodium falciparum sporozoites (PfSPZ Vaccine) administered intravenously (IV).

Detailed Description

This is a single center, Phase 1, dose escalating, randomized, double blind, controlled trial. Seventy-three healthy male volunteers, aged 18 to 35 years will be recruited. The study will have 5 study groups that will include 49 volunteers who will be intravenously injected with PfSPZ Vaccine, 8 control volunteers who will receive normal saline and 16 additional control volunteers who will be recruited at the time of controlled human malaria infection (CHMI) at 3 and 24 weeks. The control volunteers will help better assess the occurrence of AEs compared to background disease patterns that occur in this tropical area, and the performance of the vaccine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Malaria, Plasmodium Falciparum Malaria

Keywords

Malaria, Plasmodium falciparum malaria, PfSPZ Vaccine, PfSPZ Challenge, Controlled human malaria infection (CHMI)

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

67 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Group 1

Arm Type

Experimental

Arm Description

Arm Title

Group 2(A)

Arm Type

Experimental

Arm Description

Arm Title

Group 2(B)

Arm Type

Placebo Comparator

Arm Description

Arm Title

Group 3(A)

Arm Type

Experimental

Arm Description

Arm Title

Group 3(B)

Arm Type

Placebo Comparator

Arm Description

Arm Title

Group 4

Arm Type

Experimental

Arm Description

Arm Title

Group 5

Arm Type

Placebo Comparator

Arm Description

Intervention Type

Biological

Intervention Name(s)

PfSPZ Vaccine

Intervention Description

Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

Intervention Type

Biological

Intervention Name(s)

Normal Saline (Placebo)

Intervention Type

Biological

Intervention Name(s)

PfSPZ Challenge

Intervention Description

Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

Primary Outcome Measure Information:

Title

Safety and tolerability endpoints

Description

Time Frame

Vaccination to CHMI (or 28 days after last vaccination); CHMI to 28 days after CHMI

Title

Protective Efficacy after CHMI with PfSPZ Challenge (NF54) - CHMI Endpoints

Description

Time Frame

CHMI to 28 days after CHMI

Secondary Outcome Measure Information:

Title

Immune Responses after PfSPZ Vaccine

Description

Cellular and humoral immune responses will be assessed in the vaccinated volunteers and controls (including central and effector memory responses and breadth and specificity of malaria antibodies).

Time Frame

16 months

Title

Protective effect of the high dose PfSPZ Vaccine regimen

Description

Number of volunteers negative in Group 3 and Group 4 compared to Group 2 through day 28 of follow up after homologous PfSPZ Challenge (NF54) IV inoculation.

Time Frame

CHMI to day 28 after CHMI

Other Pre-specified Outcome Measures:

Title

Exploratory Endpoints - Immune Responses

Description

Malaria specific immune responses in Groups 2, 3 and 4 as compared to the malaria naïve volunteers immunized at Vaccine Research Center of the NIH (protocol VRC 312) who received 1.35x10^5 PfSPZ/dose.

Time Frame

16 months

10. Eligibility

Sex

Male

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

35 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Healthy male aged between 18 - 35 years. Good health status based on history and clinical examination. Long term or permanent resident in or near Dar-es-Salaam. Able and willing to complete the study visit schedule over the one year follow up period, including the hospitalizations required for protocol compliance. Able and willing to complete the informed consent process conducted in English. Demonstrate understanding of the study and procedures by answering 20 questions from the Protocol & Study Procedures Understanding Checklist correctly with a maximum of two attempts. Agrees to inform study doctor of medical conditions and contraindications for participation in the study. Agrees to provide contact information to the study team for a household member who will serve as an emergency contact during trial participation. Willing to be attended by a study doctor and take medications, which may be prescribed by a study doctor, during study participation. Reachable (24/7) by mobile phone during the whole study period. Agrees not to participate in another study during the study period. Agrees not to donate blood during the study period. Willing to undergo HIV, hepatitis B and hepatitis C testing. Willing to undergo controlled human malaria infection (CHMI). Exclusion Criteria: History of malaria in the past 5 years. Positive for malaria by thick blood smear at screening. Plans to travel outside the Dar-es-Salaam or Coast Region in first 12 months of the study. Previous receipt of an investigational malaria vaccine. Antibodies to parasites or selected parasite protein(s) above acceptable cut off established for the site History of arrhythmias or prolonged QT-interval or other cardiac disease or clinically significant abnormalities in electrocardiogram (ECG) at screening. History or indication of a history of drug or alcohol abuse interfering with normal social function. Use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study enrollment (inhaled and topical corticosteroids are allowed). Ongoing condition that could interfere with the interpretation of the study results or compromise the health of the volunteer. History of diabetes mellitus or cancer. Body Mass Index (BMI) below 18 or above 30 kg/m2. Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes. Positive HIV, Hepatitis B virus or Hepatitis C virus tests. Participation in any other clinical study within 30 days prior to study enrollment. Known hypersensitivity, allergy, or other contra-indications to Coartem® or Malarone® including treatment taken by the volunteer that interferes with Coartem® or Malarone®. Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia. Heterozygous or homozygous for sickle cell or homozygous for alpha thalassemia. Glucose-6-phosphate dehydrogenase deficiency Psychiatric condition that precludes compliance with the protocol; past or present psychoses; disorder requiring lithium; or within five years prior to enrollment, history of suicide plan or attempt. Any medical, psychiatric, social condition, or occupational reason that, in the judgment of the investigator, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent, increases the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. History of 3 or more other immunizations within the six months before administration of the first dose of vaccine. Clinically active tuberculosis

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Salim Abdulla, MD, PhD

Organizational Affiliation

Ifakara Health Institute

Official's Role

Principal Investigator

Facility Information:

Facility Name

Bagamoyo Research and Training Center, Ifakara Health Institute, Kingani Estate, PO Box 74

City

Bagamoyo

Country

Tanzania

12. IPD Sharing Statement

Citations:

PubMed Identifier

29943719

Citation

Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, Rutishauser T, Rothen J, Tumbo A, Mkindi C, Mpina M, Mtoro AT, Ishizuka AS, Kassim KR, Milando FA, Qassim M, Juma OA, Mwakasungula S, Simon B, James ER, Abebe Y, Kc N, Chakravarty S, Saverino E, Bakari BM, Billingsley PF, Seder RA, Daubenberger C, Sim BKL, Richie TL, Tanner M, Abdulla S, Hoffman SL. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am J Trop Med Hyg. 2018 Aug;99(2):338-349. doi: 10.4269/ajtmh.17-1014. Epub 2018 Jun 21.

Results Reference

derived

PubMed Identifier

29438525

Citation

Zenklusen I, Jongo S, Abdulla S, Ramadhani K, Lee Sim BK, Cardamone H, Flannery EL, Nguyen T, Fishbaugher M, Steel RWJ, Betz W, Carmago N, Mikolajczak S, Kappe SHI, Hoffman SL, Sack BK, Daubenberger C. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies. J Infect Dis. 2018 Apr 23;217(10):1569-1578. doi: 10.1093/infdis/jiy080.

Results Reference

derived

Learn more about this trial

We'll reach out to this number within 24 hrs